Abstract 4364982: Serum GUDCA Alleviates Cardiac Injury in Acute Myocardial Infarction by Promoting Regulatory T Cell Differentiation

Background: Regulatory T cells (Tregs) exert protective effects following acute myocardial infarction (AMI), yet their levels decline rapidly after injury. Although serum metabolites regulate various immune processes, it remains unclear whether specific metabolites can promote Treg expansion and mitigate post-AMI cardiac damage. Methods: Serum non-targeted metabolomics was performed in ST-elevation myocardial infarction (STEMI) patients stratified by Treg levels: high (Tregs/CD4 T cells > 1.5%; n = 30) vs. low (Tregs/CD4 T cells < 0.25%; n = 30) at admission. Glycoursodeoxycholic acid (GUDCA), identified as a candidate metabolite, was validated by LC-MS and ELISA. In a murine model of AMI, GUDCA (50 mg/kg/day, oral gavage) was administered post-infarction. Treg levels were analyzed by flow cytometry on Day 3. Cardiac fibrosis and function were evaluated by Sirius Red staining and echocardiography on Day 7. In vitro, naïve CD4 T cells were treated with GUDCA (100 nM) for three days to assess Treg differentiation. Cytokine profiling and ELISA were used to determine involvement of key immunoregulatory cytokines. Results: STEMI patients with higher Treg frequencies exhibited significantly elevated serum GUDCA levels. In vivo, GUDCA treatment increased Treg abundance, reduced myocardial fibrosis, and improved cardiac function post-AMI. In vitro, GUDCA directly promoted Treg differentiation from naive CD4 T cells. Mechanistically, GUDCA enhanced autocrine production of TGF-β1 and IL-2, two essential cytokines for Treg induction. Pharmacologic blockade of these cytokines abrogated GUDCA-mediated Treg differentiation. Conclusions: GUDCA, a serum metabolite elevated in STEMI patients with higher Treg levels, promotes Treg differentiation and protects against cardiac injury following AMI. These findings highlight GUDCA’s potential as a novel immunometabolic therapeutic strategy for post-infarction cardiac remodeling.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4364982
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4364982: Serum GUDCA Alleviates Cardiac Injury in Acute Myocardial Infarction by Promoting Regulatory T Cell Differentiation

Ning Cao, Hui Chen, Jiayu Li, Yang Xiang
Circulation
Cardiac Fibrosis and Remodeling
article

Abstract 4364982: Serum GUDCA Alleviates Cardiac Injury in Acute Myocardial Infarction by Promoting Regulatory T Cell Differentiation

Ning Cao, Hui Chen, Jiayu Li, Yang Xiang
article en

Abstract

Background: Regulatory T cells (Tregs) exert protective effects following acute myocardial infarction (AMI), yet their levels decline rapidly after injury. Although serum metabolites regulate various immune processes, it remains unclear whether specific metabolites can promote Treg expansion and mitigate post-AMI cardiac damage. Methods: Serum non-targeted metabolomics was performed in ST-elevation myocardial infarction (STEMI) patients stratified by Treg levels: high (Tregs/CD4 T cells > 1.5%; n = 30) vs. low (Tregs/CD4 T cells < 0.25%; n = 30) at admission. Glycoursodeoxycholic acid (GUDCA), identified as a candidate metabolite, was validated by LC-MS and ELISA. In a murine model of AMI, GUDCA (50 mg/kg/day, oral gavage) was administered post-infarction. Treg levels were analyzed by flow cytometry on Day 3. Cardiac fibrosis and function were evaluated by Sirius Red staining and echocardiography on Day 7. In vitro, naïve CD4 T cells were treated with GUDCA (100 nM) for three days to assess Treg differentiation. Cytokine profiling and ELISA were used to determine involvement of key immunoregulatory cytokines. Results: STEMI patients with higher Treg frequencies exhibited significantly elevated serum GUDCA levels. In vivo, GUDCA treatment increased Treg abundance, reduced myocardial fibrosis, and improved cardiac function post-AMI. In vitro, GUDCA directly promoted Treg differentiation from naive CD4 T cells. Mechanistically, GUDCA enhanced autocrine production of TGF-β1 and IL-2, two essential cytokines for Treg induction. Pharmacologic blockade of these cytokines abrogated GUDCA-mediated Treg differentiation. Conclusions: GUDCA, a serum metabolite elevated in STEMI patients with higher Treg levels, promotes Treg differentiation and protects against cardiac injury following AMI. These findings highlight GUDCA’s potential as a novel immunometabolic therapeutic strategy for post-infarction cardiac remodeling.

CirculationVol. 152(Suppl_3)
Beijing Friendship Hospital (CN), University of California, Davis (US)
Openalex Percentile: Top 52%
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.